摘要
目的探讨瘦素在糖尿病发病机理和治疗中的作用。方法测定120例超重和53例正常体重的2型糖尿病患者口服降糖药前后的血清胰岛素和瘦素水平。结果超重糖尿病患者比正常体重糖尿病患者瘦素水平明显升高[(5.9±3.6)和(4.1±2.6)ng/ml,P<0.05];药物治疗3个月后,格列齐特治疗组血清瘦素水平从[(5.3±3.4)ng/ml增至(6.7±3.5)ng/ml(P<0.01)],而二甲双胍治疗组从[(6.5±3.4)ng/ml降至(4.4±1.7)ng/ml(P<0.01)];罗格列酮治疗组从[(5.6±3.1)ng/ml降至(5.0±2.6)ng/ml(P<0.05)]。结论格列齐特能增加超重2型糖尿病患者瘦素分泌,而二甲双胍和罗格列酮都能降低瘦素水平。
Objective To observe the effect of anti-diabetic drugs on the plasma leptin levels in normal weight and overweight type 2 diabetic subjects. Methods The levels of leptin were determined in 120 overweight and 53 normal weight type 2 diabetec subjects before and after the administration of anti-diabetic drugs. Results The level of leptin in overweight subjects was higher than that in normal weight subjects[ （ 5.9 ± 3.6） ng/ml vs. （4.1 ± 2.6） ng/ml, P〈0.05]. Compared with that before, the level of leptin increased from （5.3±3.4） ng/ml to （6. 7±3.5） ng/ml（P〈0.01） in gliclazide group, decreased from （6.5-1-3.4） ng/ml to （4.4±1.7） ng/ml（P〈0.01） in metformin group, and from （5.6±3. 1） ng/ml to （5.0±2.6） ng/ml （P〈0. 05） in rosiglitazone group. Conclusion Gliclazide can increase the levels of leptin, while metformin and rosiglitazone decrease them in the overweight type 2 diabetic patients.
出处
《江苏医药》
CAS
CSCD
北大核心
2008年第3期220-221,共2页
Jiangsu Medical Journal
基金
江苏省自然科学基金(BK2007574)
关键词
瘦素
糖尿病
降糖药
Leptin
Diabetes mellitus
Antidiabetic drug
